AxoGen Inc. (AXGN) shares reached a 52-week high of $51.13 on Wednesday, capping a 214.19% gain over the past 12 months. The stock previously traded as low as $14.79 during the period, according to market data.
The company reported Q2 2026 revenue of $69.7 million, a 23% increase from the prior-year period and ahead of Wall Street's estimate of $67.1 million. For the trailing twelve months, revenue grew approximately 24%. AxoGen posted a net loss of $1.5 million, or $0.03 per share, in the quarter, while adjusted net income totaled $7.3 million, or $0.12 per share, meeting analyst expectations.
Analysts upgraded their outlooks following the results. H.C. Wainwright raised its price target to $53 and maintained a Buy rating. Citizens increased its target to $55, citing strong sales momentum. Truist Securities initiated coverage with a Buy rating and a $60 price target, emphasizing growth potential in the peripheral nerve repair market.
AxoGen's market capitalization stands at $2.73 billion. While the stock is near its 52-week high, an InvestingPro analysis placed it on a Most Overvalued list based on Fair Value metrics.
